Key facts
- This page summarizes Christopher Benecchi's Form 4 filing for Sage Therapeutics, Inc. (SAGE).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 21 Jun 2022, 16:02.
Christopher Benecchi - 16 Jun 2022 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- SAGE
- Reported as of
- 16 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 Jun 2022, 16:02:47 UTC
- Prior SEC filing
- 15 Feb 2022
- Next SEC filing
- 07 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Christopher Benecchi
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Christopher Benecchi filed Form 4 for Sage Therapeutics, Inc. (SAGE) on 21 Jun 2022.
Change
- Previous filing in this sequence was filed on 15 Feb 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SAGE
transaction
Derivative
Stock Options (Right to buy)
Award
- Transaction value
- $0
- Shares
- +9,500
- Change %
- Price
- $0.000000
- Shares after
- 9,500
- Date
- 16 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,500
- Exercise price
- $31.36
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The securities awarded on June 16, 2022 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 2,375 shares of common stock shall vest on the one year anniversary of June 16, 2022, with 7,125 options vesting in 36 equal monthly installments thereafter.